3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasm, Residual
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
19
Vincristine
14
Methotrexate
13
Prednisone
12
Cytarabine
12
merphos
11
blinatumomab
11
Specimen Handling
10
Mercaptopurine
10
prednylidene
9
pegaspargase
9
deltacortene
9
azathiopurine
9
N,N-dicyclohexyl-isoborneol-10-sulfonamide
9
Dexamethasone
9
Leucovorin
8
Doxorubicin
8
Biopsy
8
dexamethasone acetate
7
dexamethasone 21-phosphate
7
auricularum
7
Etoposide
7
Calcium Dobesilate
7
Thioguanine
6
Spinal Puncture
6
Daunorubicin
6
Asparaginase
6
venetoclax
5
fludarabine
5
calaspargase pegol
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Burkitt Lymphoma
×
tisagenlecleucel
×
30 days
×
Clear all
NCT03876769
2026-06-02
CASSIOPEIA
Novartis
Phase 2
Active not recruiting
121 enrolled